Literature DB >> 14687807

An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.

Paul Moayyedi1, Jon Deeks, Nicholas J Talley, Brendan Delaney, David Forman.   

Abstract

OBJECTIVES: A Cochrane systematic review on the efficacy of Helicobacter pylori (H. pylori) eradication therapy in nonulcer dyspepsia concluded that this intervention had a small but statistically significant effect in curing symptoms. A systematic review in the Annals of Internal Medicine suggested that there was no statistically significant effect of H. pylori eradication therapy on nonulcer dyspepsia symptoms. We updated the Cochrane review and explored reasons for these discrepant results.
METHODS: In our update of the Cochrane review we included randomized controlled trials evaluating H. pylori eradication in nonulcer dyspepsia published up to September, 2002. A statistician and the lead author of two negative randomized controlled trials explored reasons for the differences between the Cochrane and Annals systematic reviews according to the review methodology, data analyzed, and statistical methods. Sensitivity analyses were undertaken to evaluate which differences had an impact on the review conclusions.
RESULTS: The updated review identified 12 trials evaluating H. pylori eradication versus placebo antibiotics in 2903 patients. H. pylori eradication reduced nonulcer dyspepsia (nonulcer dyspepsia relative risk = 0.91; 95% CI = 0.86-0.95). We identified five differences in methodology between the Cochrane and Annals reviews. The Annals review included all dual, triple, and quadruple H. pylori eradication therapies searched until December, 1999; did not contact authors for further information; included abstracts; and assumed that dropouts were treatment failures. The Cochrane review included only those therapies proved to be successful in eradicating H. pylori; searched until May, 2000; contacted authors for further information; included abstracts only if further information was available; and excluded dropouts from the analysis. Not including trials published in 2000 reduced the number of trials in the review and the number of patients evaluated, changing the conclusions from evidence of benefit to benefit not being proved. The method of statistical analysis did not alter conclusions when all studies were included.
CONCLUSIONS: The results of systematic reviews in a rapidly developing field depend on inclusion of all relevant studies. There is evidence for a small benefit of eradicating H. pylori in nonulcer dyspepsia, and this is confirmed by updating the Cochrane systematic review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14687807     DOI: 10.1111/j.1572-0241.2003.08724.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  48 in total

1.  Overlap syndrome of functional dyspepsia and irritable bowel syndrome - are both diseases mutually exclusive?

Authors:  Hidekazu Suzuki; Toshifumi Hibi
Journal:  J Neurogastroenterol Motil       Date:  2011-10-31       Impact factor: 4.924

2.  Eradicating H pylori.

Authors:  Brendan Delaney; Paul Moayyedi
Journal:  BMJ       Date:  2004-06-12

3.  Functional dyspepsia.

Authors:  Rita Brun; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

Review 4.  Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations?

Authors:  Laura Noddin; Michael Callahan; Brian E Lacy
Journal:  MedGenMed       Date:  2005-08-29

5.  Who benefits from Helicobacter pylori eradication?

Authors:  Brendan C Delaney
Journal:  BMJ       Date:  2006-01-28

6.  Functional dyspepsia, delayed gastric emptying, and impaired quality of life.

Authors:  N J Talley; G R Locke; B D Lahr; A R Zinsmeister; G Tougas; G Ligozio; M A Rojavin; J Tack
Journal:  Gut       Date:  2005-12-01       Impact factor: 23.059

7.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

8.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

Review 9.  Managing dyspepsia.

Authors:  Alexander C Ford; Paul Moayyedi
Journal:  Curr Gastroenterol Rep       Date:  2009-08

10.  The Role of RANTES Promoter Polymorphism in Functional Dyspepsia.

Authors:  Tomomitsu Tahara; Tomoyuki Shibata; Hiromi Yamashita; Ichiro Hirata; Tomiyasu Arisawa
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.